Literature DB >> 2698500

[Cellular localization, half-life, and secretion of peptide YY].

F Lluis1, M Fujimura, G Gómez, J A Salvá, G H Greeley, J C Thompson.   

Abstract

Tissue and plasma concentration of peptide YY (PYY) were measured by means of a radioimmunoassay (RIA) developed in our laboratory, using a specific PYY antiserum generated in New Zealand white rabbits against synthetic PYY, and dextran-coated charcoal to terminate the assay. Cellular localization of PYY was studied immunohistochemically using the peroxidase-antiperoxidase (PAP) technique. The highest tissue concentration of PYY was found in the mucosa of the terminal ileum and colon. PYY-containing secretory granules were primarily found in the basal pole of open-type endocrine cells. Basal plasma concentration of PYY was 70 +/- 9 pg/ml and rose to 357 +/- 30 pg/ml during the IV administration of PYY at 400 pmol/kg-h. A significant correlation was found (r = 0.94, p less than 0.05) between dose of PYY (12.5, 25, 50, 100, 200, 400 pmol/kg-h, IV) and plasma concentration of PYY. The calculated half-life of PYY in plasma was 8.3 +/- 1.9 minutes. Plasma concentration of PYY during the intraduodenal administration of sodium oleate (150 +/- 20 pg/ml) or long-chain triglyceride (187 +/- 37 pg/ml) was similar to plasma concentration of PYY obtained during the IV administration of PYY at 100 pmol/kg-h. Plasma concentration of PYY raised (126 +/- 10 pg/ml) after the administration of bombesin (400 pmol/kg-h, IV). Bile enhanced release of PYY. The present study suggests a hormonal role for PYY.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2698500

Source DB:  PubMed          Journal:  Rev Esp Fisiol        ISSN: 0034-9402


  8 in total

Review 1.  Gut hormones: the future of obesity treatment?

Authors:  Anne K McGavigan; Kevin G Murphy
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 2.  Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.

Authors:  Gitanjali Srivastava; Caroline Apovian
Journal:  Curr Obes Rep       Date:  2018-06

3.  Can Bayliss and Starling gut hormones cure a worldwide pandemic?

Authors:  R V Scott; T M Tan; S R Bloom
Journal:  J Physiol       Date:  2014-09-12       Impact factor: 5.182

Review 4.  The future role of gut hormones in the treatment of obesity.

Authors:  Rachel C Troke; Tricia M Tan; Steve R Bloom
Journal:  Ther Adv Chronic Dis       Date:  2014-01       Impact factor: 5.091

5.  Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity.

Authors:  Akila De Silva; Stephen R Bloom
Journal:  Gut Liver       Date:  2012-01-12       Impact factor: 4.519

Review 6.  Peripheral Pathways in the Food-Intake Control towards the Adipose-Intestinal Missing Link.

Authors:  Hugo Mendieta Zerón; Ma Victoria Domínguez García; María Del Socorro Camarillo Romero; Miriam V Flores-Merino
Journal:  Int J Endocrinol       Date:  2013-12-05       Impact factor: 3.257

7.  The homeostatic dynamics of feeding behaviour identify novel mechanisms of anorectic agents.

Authors:  Thomas M McGrath; Eleanor Spreckley; Aina Fernandez Rodriguez; Carlo Viscomi; Amin Alamshah; Elina Akalestou; Kevin G Murphy; Nick S Jones
Journal:  PLoS Biol       Date:  2019-12-05       Impact factor: 8.029

Review 8.  The L-Cell in Nutritional Sensing and the Regulation of Appetite.

Authors:  Eleanor Spreckley; Kevin Graeme Murphy
Journal:  Front Nutr       Date:  2015-07-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.